Wells Fargo & Company Issues Positive Forecast for Halozyme Therapeutics (NASDAQ:HALO) Stock Price

Halozyme Therapeutics (NASDAQ:HALO – Free Report) had its target price increased by Wells Fargo & Company from $95.00 to $110.00 in a research note released on Friday morning,Benzinga reports. They currently have an equal weight rating on the biopharmaceutical company’s stock.

Several other research firms also recently commented on HALO. Stifel Nicolaus set a $130.00 price objective on Halozyme Therapeutics in a report on Friday, October 16th. HC Wainwright increased their target price on shares of Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, October 7th. Citizens Jmp upped their price objective on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Finally, Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $106.09.

Read Our Latest Report on Halozyme Therapeutics

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO traded down $19.33 during mid-day trading on Friday, reaching $103.63. 6,162,578 shares of the company traded hands, compared to its average volume of 2,186,879. The firm has a market cap of $11.76 billion, a PE ratio of 26.37, a PEG ratio of 0.49 and a beta of 0.92. Halozyme Therapeutics has a 52 week low of $61.22 and a 52 week high of $134.00. The company’s 50 day moving average price is $115.19 and its 200-day moving average price is $84.73. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last issued its earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.09. The firm had revenue of $492.97 million during the quarter, compared to analyst estimates of $491.63 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. Halozyme Therapeutics’s revenue for the quarter was up 39.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.72 earnings per share. On average, equities analysts expect that Halozyme Therapeutics will post 8.32 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the sale, the director directly owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $109.40, for a total value of $2,188,000.00. Following the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at $83,995,132. The trade was a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 125,852 shares of company stock worth $13,538,046 over the last 90 days. 2.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Hilton Head Capital Partners LLC acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $33,000. CoreCap Advisors LLC grew its position in Halozyme Therapeutics by 98.0% during the third quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 150 shares during the period. MidFirst Bank acquired a new stake in Halozyme Therapeutics during the second quarter valued at $27,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Halozyme Therapeutics in the second quarter valued at $28,000. Finally, Quantbot Technologies LP purchased a new position in Halozyme Therapeutics in the second quarter valued at $30,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

  • Positive Sentiment: Q3 revenue rose 39% year over year to $493 million and adjusted EPS of $2.39 beat estimates. Record royalty revenue increased 44% to $341 million. Halozyme also raised its 2026 revenue, royalty, EBITDA and adjusted EPS guidance. Q3 results and guidance
  • Positive Sentiment: The FDA approved Johnson & Johnson’s RYBREVANT FASPRO, which uses Halozyme’s ENHANZE technology, for certain patients with advanced head and neck cancer. The expanded use could support future royalties. FDA approval
  • Positive Sentiment: Halozyme said its analysis of Medicare’s drug-price negotiation rule indicates zero to minimal impact on royalty revenue through at least 2035, easing a potential long-term concern. Medicare rule assessment
  • Neutral Sentiment: Citizens JMP raised its price target to $149 and maintained an outperform rating, while Wells Fargo raised its target to $110 but kept an equal-weight rating—signaling differing views on further upside. Citizens JMP rating
  • Negative Sentiment: Despite the earnings beat and higher guidance, reports noted a negative share reaction and questions around the guidance reset, suggesting results may not have met elevated investor expectations. The Merck patent dispute also remains an investor focus. Earnings reaction and guidance questions

Halozyme Therapeutics Company Profile

(Get Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.

Further Reading

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.